Medical Implant Business Investment Opportunities in Haifa

The company develops human bone tissue for implantation in patients with bone fractures, instability in the spine, or bone gaps following trauma or previous surgery. - We are currently in the development stage, hence there is no revenue generation and the figures are not given. - The product is tailored for a specific patient because it uses bone cells and blood components. - Therefore, this product is individualized for a patient and should not be rejected. - We have already successfully passed the FDA pre-IND process with a positive feedback. - Patents have already been issued in the EU, USA, Switzerland, and Israel. - The method, its efficiency, and safety were described in two scientific papers published in. Highly ranked peer-reviewed journals. - Have conducted preliminary testing to demonstrate the feasibility of the product. - Led by a highly qualified CEO who is an expert in bone cell culturing and has multiple qualifications like MD, MOrthop, MBA, and FRCS (England). - It is expected to require an additional 2 years after securing funding to obtain necessary approvals from the FDA and European authorities. - The bone grafting market is estimated to be above USD 10 billion. - Since currently there is no clinically used method for personalized bone grafting material supplementation, the appearance of such a product will even increase the market evaluation.

The company develops human bone tissue for implantation in patients with bone fractures, instability in the spine, or bone gaps following trauma or previous surgery. - We are currently in the development stage, hence there is no revenue generation and the figures are not given. - The product is tailored for a specific patient because it uses bone cells and blood components. - Therefore, this product is individualized for a patient and should not be rejected. - We have already successfully passed the FDA pre-IND process with a positive feedback. - Patents have already been issued in the EU, USA, Switzerland, and Israel. - The method, its efficiency, and safety were described in two scientific papers published in. Highly ranked peer-reviewed journals. - Have conducted preliminary testing to demonstrate the feasibility of the product. - Led by a highly qualified CEO who is an expert in bone cell culturing and has multiple qualifications like MD, MOrthop, MBA, and FRCS (England). - It is expected to require an additional 2 years after securing funding to obtain necessary approvals from the FDA and European authorities. - The bone grafting market is estimated to be above USD 10 billion. - Since currently there is no clinically used method for personalized bone grafting material supplementation, the appearance of such a product will even increase the market evaluation.